Novel agents for the treatment of pancreatic cancer

Journal of the Pancreas

Volumn 15, Issue 2, 2014, Pages 110-113

  Brennan, Gregory T ^a   Relias, Valerie ^b   Saif, Muhammad Wasif ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Antibodies; Heat shock proteins; HSP90 heat shock proteins; Listeria monocytogenes; Mesothelin; Monoclonal; Pancreatic neoplasms; STA 9090; Vaccines

Indexed keywords

ANTINEOPLASTIC AGENT; CRS 207; CYCLOPHOSPHAMIDE; ENSITUXIMAB; GANETESPIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HEAT SHOCK PROTEIN 90; MUCIN 5AC; NEO102; TANESPIMYCIN; TUMOR VACCINE; UNCLASSIFIED DRUG;

COLORECTAL CANCER; CONFERENCE PAPER; HUMAN; LISTERIA MONOCYTOGENES; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS METASTASIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC);

EID: 84897840607     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: 10.6092/1590-8577%2F2320     Document Type: Conference Paper

References (13)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan; 63(1):11-30.
2. Dung T, Wang-Gillam A, Picozzi Jr V, Greten TF, Crocenzi TS, Springett GM, Morse M, Zeh H, Cohen DJ, Fine RL, Onmers B, et al. A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results. J Clin Oncol, 2014;32(suppl 3):Abstract 177.
3. Patel SP, Morse M, Beg MS, Azad NS, Beaston MA, Mavroukakis S, Arlen PM. J Clin Oncol 2014;32(suppl 3):Abstract 243.
4. Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. 2010;29:2893-2904.
5. Takikita M, Altekruse S, Lynch CF, Goodman MT, Hernandez BY, Green M, Cozen W, Cockburn M, et al. Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res 2009;69:2950- 55.
6. Inaguma S, Kasai K, Ikeda H. Gl11 facilitates the migration and invasion of pancreatic cancer cells theough MUC5AC-mediated attenuation of E-cahedrin. Oncoge 2011;30:714-23.
7. Patel SP, Bristol A, Saric O, Wang X-P, Dubeykovskiy A, Arlen PM, Morse MA. Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. Cancer Immunol Immunother 2013:62:10 11-19.
8. Morse M, Diaz LA, Azad NS, Laheru D, Haley S, Sleer LS, Arlen PM. A phase Ib/IIa study of NEO-102: A therapeutic antibody totreat pancreatic and colorectal cancers. J Clin Oncol 2012;30(suppl 4):233.
9. Thota R, Goff LW, Chan E, Berlin J, Jones CM, McClanahan P, Ayers GD, Cardin DB. A phase II study of ganetespib (G) as second- or third-line therapy for metastatic pancreatic cancer (MPC). J Clin Oncol 2014;32(suppl 3):Abstract 297.
10. Choi HK, Lee K. Recent updates on the development of ganetespib as a HSP90 inhibitor. Arch Pharm Res 2012;35:1855-59.
11. Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Guo W, Inoue T, Rosen LS. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the HSP90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 2013;13:152-62.
12. Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K. Ganetespib, a unique triazolone-containing HSP90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2011;11(2):475-84.
13. Kauh JS, Harvey RD, Owonikoko TK, El-Rayes BF, Shin DM, Murali S, Lewis CM, Karol MD, Teofilovici F, Du Y, Fu H, Khuri FR, Ramalingam SS. A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumors malignancies. J Clin Oncol 2012 3094.